Equities

Day One Biopharmaceuticals Inc

DAWN:NSQ

Day One Biopharmaceuticals Inc

Actions
  • Price (USD)16.39
  • Today's Change0.63 / 4.00%
  • Shares traded2.37m
  • 1 Year change+35.01%
  • Beta-1.4494
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy2
Outperform7
Hold1
Sell0
Strong Sell0

Share price forecast in USD

The 9 analysts offering 12 month price targets for Day One Biopharmaceuticals Inc have a median target of 39.00, with a high estimate of 48.00 and a low estimate of 28.00. The median estimate represents a 137.95% increase from the last price of 16.39.
High192.9%48.00
Med137.9%39.00
Low70.8%28.00

Earnings history & estimates in USD

On Oct 30, 2024, Day One Biopharmaceuticals Inc reported 3rd quarter 2024 earnings of 0.38 per share. This result exceeded the -0.41 consensus loss of the 8 analysts covering the company and outperformed last year's 3rd quarter results by 0.92.
The next earnings announcement is expected on Mar 03, 2025.
Average growth rate+20.68%
Day One Biopharmaceuticals Inc reported annual 2023 losses of -2.37 per share on Feb 26, 2024.
Average growth rate+21.91%
More ▼

Revenue history & estimates in USD

Day One Biopharmaceuticals Inc had 3rd quarter 2024 revenues of 93.76m. This bettered the 23.55m consensus of the 8 analysts covering the company.
Average growth rate+348.18%
Day One Biopharmaceuticals Inc did not report revenues for the full year 2023. However, during the prior year the company reported revenues of 0.00.
Average growth rate0.00%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.